Polymorphisms of the human UDP-glucuronosyltransferase (UGT) 1A7 gene in colorectal cancer

C P Strassburg, A Vogel, S Kneip, R H Tukey, M P Manns

Background: Genetic polymorphisms in the human UDP-glucuronosyltransferase-1A7 (UGT1A7) gene are detected and significantly correlated with sporadic colorectal carcinoma. UGT1A7, which has recently been demonstrated to glucuronidate environmental carcinogens, is now implicated as a cancer risk gene. A silent mutation at codon 11 and missense mutations at codons 129, 131, and 208 lead to the description of three polymorphic alleles designated UGT1A7*2, UGT1A7*3, and UGT1A7*4.

Methods: UGT1A7 polymorphisms were analysed by polymerase chain reaction amplification and sequencing, as well as temperature gradient gel electrophoresis in 210 healthy blood donors and 78 subjects with colorectal cancer.

Results: Homozygous wild-type UGT1A7 alleles were present in 20% of normal controls but were only detected in 9% of patients with colorectal carcinoma (odds ratio (OR) 0.39 (95% confidence interval (CI) 0.17–0.92); p<0.03). Analysis of individual polymorphic alleles identified a highly significant association between the presence of UGT1A7*3 alleles and colorectal cancer (OR 2.75 (95% CI 1.6–4.71); p<0.001). Recombinant expression of UGT1A7 polymorphic cDNA in eukaryotic cell culture showed reduced carcinogen glucuronidation activity in comparison with wild-type UGT1A7. UGT1A7 may therefore represent a modifier gene in colorectal carcinogenesis.

Conclusion: We have identified a potential novel risk factor in sporadic colorectal cancer which may contribute to the identification of risk groups and to the elucidation of factors involved in colon carcinogenesis.

The human UDP-glucuronosyltransferase (UGT) UGT1A7 belongs to a family of nine proteins encoded at the human UGT1A locus on chromosome 2q37, which is highly conserved in vertebrate organisms. UGTs catalyse the conversion of hydrophobic substrates to inactive hydrophobic β-D-glucopyranosiduronic acids (glucuronides) which can undergo facilitated renal or biliary elimination. Target substrates for glucuronidation consist of compounds from many diverse chemical classes, including dietary byproducts, endogenous metabolites such as steroids and bilirubin, many therapeutic drugs, and many environmental mutagens, such as polycyclic and heterocyclic aromatic hydrocarbons as well as heterocyclic amines. In addition, glucuronidation confers metabolic stability to many other xenobiotics which may undergo biotransformation to toxic metabolites.

In humans, tissue specific expression of the UGT1A locus gene products has been demonstrated. UGT1A7, UGT1A8, and UGT1A10 are not expressed in hepatic tissues and have been shown to be differentially regulated in gastrointestinal organs such as the oesophagus, stomach, small intestine, and colon. In addition, regulation and function of the UGT1A genes has been linked to gastrointestinal carcinogenesis. Analysis of human cancers has shown differential regulation of UGT expression in tumour tissues with an impact on epithelial glucuronidation activity. In gastric mucosa, UGT1A1 regulation leading to interindividual variations in UGT activity has been implicated as a cancer risk factor while in oesophageal cancer, downregulation of UGT1A7 transcript is correlated with a decrease in overall oesophageal benzo(a)pyrene metabolite glucuronidation. This is significant as the cloning and characterisation of UGT1A7 has demonstrated its capacity to glucuronidate polycyclic aromatic hydrocarbons as well as dietary derived heterocyclic amines, both of which are known carcinogens. These findings prompted us to predict that alterations in UGT1A7 gene expression or in the functional properties of UGT1A7 may be an indicator of potential cancer risk. Hence we examined UGT1A7 as a target gene for the evaluation of polymorphisms and their relation to gastrointestinal cancer.

Colorectal cancer (CRC) accounts for 9.7% of all newly diagnosed carcinomas. Pedigree and genetic analyses have identified a heritable aetiology in 15–20% of colorectal cancers. This has been linked to mismatch repair genes which have thus been indicated as colon cancer susceptibility markers. For a proportion of the remaining sporadic cancers, carcinogenesis based on mutagen mediated genotoxicity capable of initiating neoplastic transformation represents a potential mechanisms. The combined risk of carcinogenesis may therefore be determined by the outcome of an interaction between genetically defined biochemical defence mechanisms of the cell, such as those provided by the well characterised UGT super gene family, and the environmentally defined exposure to carcinogens.

In this study we show the significant association of CRC with polymorphisms of the UGT1A7 carcinogen metabolising UGT gene.

MATERIALS AND METHODS

Patients

Patient samples were collected from consecutive patients attending the Department of Gastroenterology and Hepatology, and Department of Transfusion Medicine, Hannover Medical School in 1999 and 2000. All patients were of German Caucasian ancestry. Written consent was obtained from all patients.

Abbreviations: UGT, UDP-glucuronosyltransferase; CRC, colorectal cancer; TGGE, temperature gradient gel electrophoresis; PhIP, amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.

See end of article for authors’ affiliations

Correspondence to: Dr C P Strassburg, Department of Gastroenterology and Hepatology, Hannover Medical School, Carl-Neuburg Str 1, 30625 Hannover, Germany; strassburg.christian@mh-hannover.de

Accepted for publication 7 August 2001

www.gutjnl.com

Gut 2002;50:851–856
patients prior to blood sampling and the ethics committee of Hannover Medical School approved the study protocol. The following patient sample groups were studied. As controls, healthy blood donors were studied (n=210, females 92/males 118; mean (SD) age 48 (21) years (range 19–85)). Colorectal cancer patients (n=78, females 28/males 50; mean (SD) age 63.3 (11) years (range 38–85)) had sporadic colorectal cancer identified by exclusion of the Amsterdam II criteria.20 The diagnosis was based on histological evaluation of endoscopic or surgical specimens in each patient.

**Genomic DNA**

Genomic DNA was prepared from full blood samples using the QiaAmp isolation system according to the recommendations of the manufacturer (Qiagen, Hilden, Germany). Concentrations were determined by spectrophotometry at 260 and 280 nm and samples were stored in 10 mM Tris/EDTA buffer (pH 8.0) at 4°C until analysis.

**Analysis of UGT1A7 exon 1 sequences**

The human UGT1A gene locus consists of divergent individually regulated exon 1 sequences at the 5′ end followed by one copy of exons 2–5 at the 3′ end. Each individual UGT1A tran
tiscript therefore comprises unique exon 1 sequences combined with exon 2–5 sequences present on all UGT1A transcripts. Therefore, in order to study a specific UGT1A gene, examination of exon 1 sequence is required. UGT1A7 exon 1 sequences were amplified by polymerase chain reaction. The forward primer was located from bp 38 upstream of the ATG start codon of UGT1A7 (GenBank accession No U39570) (5′-gcggctcgagccacttactatattataggagct-3′); the reverse primer was located between bp 855 and 829 (GenBank accession No U89507) (5′-gggatatccataggcactggctttccctgatgaca-3′). Location of the upstream primer outside the open reading frame was required to obtain specificity of the amplification reaction because exon 1 sequences of UGT1A7–10 share 93% homology. A 916 bp product was amplified in a volume of 100 µl containing 10 mM KCl, 20 mM Tris HCl (pH 8.8), 10 mM ammonium sulphate, 2 mM magnesium sulphate, 1% Triton X-100, 0.2 µM each dNTP, 20 ng of genomic DNA, 2 µM of primers, and 5 units of VENT (exo-) DNA polymerase (NEB, Beverly, Massachusetts, USA). After a hot start at 94°C for three minutes, 30 cycles of 94°C for 30 seconds, 57°C for 30 seconds, and 72°C for 90 seconds were run on a Perkin Elmer GeneAmp PCR 2400 system. The products were visualised by 2% agarose gel electrophoresis (TGGE) to detect DNA heteroduplex formation. Two separate experiments were optimised to detect point mutations at codons 129/131 as well as at codon 208 using the

**Site directed mutagenesis**

Complementary DNA containing the polymorphic UGT1A7*4 (GenBank accession No AF296126), UGT1A7*2 (GenBank accession No AF296127), and UGT1A7*3 (GenBank accession No AF296128) alleles were generated by polymerase chain reaction based site directed mutagenesis. The recently cloned and published wild-type cDNA sequence (GenBank accession No U89507) was used as template DNA. The mutagenesis strategy employed three primer pairs. The first primer pair (sense primer 1: 5′-cggatatcaggtttttgaggtctctctcag-3′; antisense primer 2: ccagaggctatttctaga-3′) spans the entire open reading frame of UGT1A7, includes restriction endonuclease sites for directional cloning, and has previously been published.1 The second primer pair anneals to the sense and antisense strand between base pairs 370 and 405 covering the missense base pair changes at codon 129 and at codon 131 (sense primer 3: 5′-ggcaggtgttgtaagcacaacaaattagtaaa-3′, antisense primer 4: 5′-tctactaatattttgctctaaaacacttg-3′). The third primer pair anneals to the sense and antisense strand between base pairs 603 and 637 covering the missense base pair changes at codon 208 (sense primer 5: 5′-gacctaggaagagatcaggggagctca-3′, antisense primer 6: 5′-gctagtgtgtgtgcctctctcttggaatgct-3′). The UGT1A7*4 polymorphism was generated by separate amplification of the fragments generated with primers 1 and 6 as well as 5 and 2. After annealing of the denatured fragments in the region covered by primers 5 and 6 and an extension reaction, the full length product of 1593 bp was amplified using primers 1 and 2. The UGT1A7*2 polymorphism was generated in a similar fashion using primers 1 and 4 as well as 5 and 2 for the initial amplification and primers 1 and 2 to amplify the 1593 bp product after the extension reaction. The UGT1A7*3 polymorphism which combines missense mutations at codons 129, 131, and 208 required two rounds of annealing and amplification. Firstly, three fragments were generated by polymerase chain reaction using primers 1 and 4, primers 3 and 6, and primers 5 and 2. Next, the denatured fragments between primers 3 and 6 as well as between primers 5 and 2 were annealed for the extension reaction and subsequently amplified with primers 3 and 2. This product was denatured and annealed with the fragment between primers 1 and 4. The final amplification using primers 1 and 2 resulted in a full length product of 1593 base pairs. The products were purified after amplification to eliminate contamination with primers and template. Polymerase chain reaction was performed under the conditions described for the UGT1A7 exon 1 amplification above. All sequences were confirmed by sequencing of both strands. The wild-type UGT1A7*1 as well as the UGT1A7*2, UGT1A7*3, and UGT1A7*4 CDNs were inserted into the multidiscion site of
The UGT1A7*4 allele is characterised by a silent mutation at codon 11 is silent. At codons 129, 131, and 208, mutations lead to amino acid substitutions. Sequence analysis identified the presence of three different polymorphisms designated UGT1A7*2, UGT1A7*3, and UGT1A7*4. Exchanges at codons 112 and 208 (UGT1A7*4) as well as the polymorphisms at codons 129 and 131 (UGT1A7*2) did not occur individually (GenBank Nos AF296226, AF296227, AF296228).

Expression and characterisation of UGT1A7*1, UGT1A7*2, UGT1A7*3, and UGT1A7*4

Human embryonic kidney (HEK293) cells were transfected with pCDNA3.1 plasmids containing the UGT1A7*1, UGT1A7*2, and UGT1A7*3 cDNAs as previously described. Cells were harvested after 72 hours and lysed by freeze thawing. Expression of equal amounts of the different recombinant UGT proteins was controlled by β-galactosidase transfection and western blot using a rabbit anti-exon 2 antibody as reported previously. The following substrates were resuspended in methanol at a concentration of 5 mM: 4-nitropheno1-1, 1-naphthol, 4-methylumbelliferone, 4-tert-butylphenol, 7-hydroxybenzo(a)pyrene, 8-hydroxybenzo(a)pyrene, 7/8-hydroxybenzo(a)pyrene, 9-hydroxybenzo(a)pyrene, and amino-1-aryl-6-phenylimidazo(4.5-β)-pyridine (PhIP). Whole cell extracts (50 µg) expressing recombinant protein in reaction buffer (50 mM Tris-Cl (pH 7.6), 10 mM MgCl2) were used for catalytic activity assays in a modification of the method of Bansal and Gessner,23 as previously described. The UDP-glucuronic acid concentration was 250 µM. The “C”-labelled glucuronides were visualised by autoradiography, and quantitated using a Fujifilm BAS-1000 phosphoimager (Raytest GmbH, Straubinghardt, Germany) and TINA 2.0 software (Raytest GmbH, Straubinghardt, Germany) for calculation of specific activities that were expressed as pmol glucuronide formed/min/mg of recombinant protein. Autoradiography hard copies were additionally analysed with a GS-710 calibrated imaging densitometer (BioRad Laboratories, Hercules, California, USA) using the Quantity One software package.

RESULTS AND DISCUSSION

The risk of cancer development is defined by genetic predisposition and environmental mechanisms such as exposure to cellular mutagens.24 The cellular interaction with putative carcinogens is influenced by the activity of detoxification enzymes expressed in tissues with xenobiotic contact.23 Therefore, the link between genetic polymorphisms of carcino-gen metabolising enzymes and human cancer represents an attractive model combining genetic predisposition and environmental exposure.25

Detection of three polymorphic sites within exon 1 of the UGT1A7 gene

In this study, UGT1A7 polymorphisms were analysed in 288 Northern German Caucasian patients, which included 210 healthy controls and 78 patients with CRC. Confirming an earlier report analysing American patients,25 three polymorphic sites with a total of five individual base pair changes leading to three amino acid changes were detected (figs 1, 2). The sequencing data were confirmed by a TGGE assay developed for the detection of the 129K/R131K as well as the 208R missense mutations (fig 3). The combined differences are represented on three alleles defined as UGT1A7*2 (GenBank accession No (acc) AF296127), UGT1A7*3 (GenBank acc AF296128), and UGT1A7*4 (GenBank acc AF296126).

The UGT1A7*4 allele is characterised by a silent mutation within the endoplasmic reticulum signal peptide domain14 which is present in all UGT1A proteins with the exception of...
UGT1A10. The second change is represented by the missense mutation at codon 208. Codon 208 falls within a region of sequence conserved not only in the first exons of UGT1A7–10 but in all members of the UGT1A family (fig 2). The presence of a Leu-127, which is present in all UGT1A proteins, affects highly conserved sequence of the UGT protein. Following the identification of polymorphic UGT1A7 alleles, the occurrence of the three missense mutations in normal controls as well as in CRC was determined (table 1). We used a control group of 210 healthy blood donors in addition to a cancer group of 78 CRC patients. The number of patients studied resulted in a statistical power of 90% in the present study. In the control population, homozygosity for wild-type UGT1A7 was confirmed in 20%. Of the other UGT1A7 alleles, UGT1A7*2/*1 was found in 25%, UGT1A7*2/*2 in 12%, and UGT1A7*3/*3 in 10% of individuals. The occurrence of at least one allele of UGT1A7*3 was found to be in 27% and the allelic frequency was 0.17 (table 1). In a previously reported series, 144 healthy blood donors from the Boston area were analysed and found to exhibit an allelic frequency of 0.361 for the UGT1A7*3 polymorphic allele which contrasts with our findings in a homogeneous group of 210 German blood donors all of Caucasian descent from Northern Germany. Unfortunately, the study by Guillemette et al did not provide data on subjects’ genetic backgrounds. It is therefore possible that differences in genetic/ethnic background and immigration patterns in the USA versus a more homogeneous population in Northern Germany contribute to the observed differences. In the present study, we compared a defined control group with patients with manifest CRC who were also of German descent from the same area, and therefore shared the genetic background.

In the CRC group, a striking difference in the occurrence of UGT1A7 polymorphisms was detected (table 1, fig 4). Only 9% of CRC patients exhibited the UGT1A7 homozygous wild-type (p=0.03, OR 0.39 (95% CI 0.17–0.92)). The high incidence of CRC patients exhibited the UGT1A7 homozygous wild-type genetic background.

Table 1  Association of UGT1A7 polymorphisms with colorectal carcinoma

<table>
<thead>
<tr>
<th>UGT1A7 alleles</th>
<th>Normal controls† (n=210) (%)</th>
<th>Colorectal cancer† (n=78) (%)</th>
<th>p Value</th>
<th>OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>UGT1A7*1/*1</td>
<td>16 (7)</td>
<td>3 (4)</td>
<td>0.03</td>
<td>0.39 (0.17–0.92)</td>
</tr>
<tr>
<td>UGT1A7*1/*2</td>
<td>25 (12)</td>
<td>10 (13)</td>
<td>0.12</td>
<td>2.26 (1.09–4.68)</td>
</tr>
<tr>
<td>UGT1A7*1/*3</td>
<td>20 (10)</td>
<td>15 (19)</td>
<td>0.04</td>
<td>2.39 (1.15–4.99)</td>
</tr>
<tr>
<td>UGT1A7*3/*2</td>
<td>17 (8)</td>
<td>15 (19)</td>
<td>0.63</td>
<td>2.10</td>
</tr>
<tr>
<td>UGT1A7*3/*4</td>
<td>35 (17)</td>
<td>15 (19)</td>
<td>0.10</td>
<td>2.10</td>
</tr>
<tr>
<td>UGT1A7*4/*1</td>
<td>0</td>
<td>1 (1)</td>
<td>NS</td>
<td>1.0</td>
</tr>
<tr>
<td>UGT1A7*4/*2</td>
<td>0</td>
<td>0</td>
<td>NS</td>
<td>1.0</td>
</tr>
<tr>
<td>Presence of UGT1A7*3</td>
<td>56 (27)</td>
<td>39 (50)</td>
<td>&lt;0.001</td>
<td>2.75 (1.6–4.71)</td>
</tr>
</tbody>
</table>

The wild-type allele of UGT1A7 was significantly more prevalent in the tumour free control group (OR 0.39, 95% CI 0.17–0.92). The association of polymorphic UGT1A7 alleles with colorectal cancer was significant for the UGT1A7*3/*1 and the UGT1A7*3/*2 genotypes. When the data were analysed for the presence of UGT1A7*3 alleles a highly significant association with colorectal cancer (CRC) was found. This analysis identified the presence of the UGT1A7*3 allele as a risk factor for CRC. The frequency of the UGT1A7*3 allele was 0.17 in normal controls and 0.301 in CRC patients.

p values calculated by two tailed Fisher’s exact test
OR, odds ratio; CI, confidence interval; NS, not significant
†All patients were of Northern German Caucasian descent.
from that reported for other allelic associations of metabolising enzymes and cancer.8–11

When these data were further analysed for the presence of the different defined genotypes (table 1, fig 4), as characterised in fig 1, a statistically significant genotypic association with CRC was observed with UGT1A7*3/*1 as well as with UGT1A7*3/*2. This analysis identified the UGT1A7*3 allele as a risk factor in CRC. The allelic frequency of UGT1A7*3 in sporadic CRC was 0.30. Thus when the presence of UGT1A7*3 alleles was compared in normal control subjects and CRC patients, this difference was highly significant (p<0.001, OR 4.03; 95% CI 1.6–9.71). Additionally, logistical regression analysis demonstrated that tumour occurrence was dependent on the presence of polymorphic UGT1A7 alleles (p=0.025), in particular UGT1A7*3 (p=0.001), but was independent of sex (p=0.17).

Modification of catalytic UDP-glucuronosyltransferase 1A7 activity

To our knowledge, these data provide the first evidence of a significant genetic link between the gene of a carcinogen metabolising enzyme and sporadic CRC. These findings raise significant aetiological implications for the disease. In sporadic CRC, environmental as well as genetic factors have been suggested, yet never directly demonstrated. An attractive hypothesis would suggest that alteration of xenobiotic or carcinogen glucuronidation in individuals expressing polymorphic alleles would affect exposure with these agents to the proximal as well as the downstream intestinal tract which could determine the rate of inflammation as well as cytotoxicity and genotoxicity.12–14 To address this issue, polymorphic UGT1A7 alleles were expressed and characterised for differences in catalytic activity. We demonstrated that glucuronidation of benzo(a)pyrene metabolites and PhIP were markedly altered (table 2). For UGT1A7*3 that was identified as a main allelic association and risk factor in CRC, catalytic analysis indicated loss of activity for all tested substrates. The UGT1A7*4 allele exhibited substantially reduced phenolic UGT activities and undetectable activity towards carcinogen metabolites such as 8- and 9-hydroxybenzo(a)pyrene and the human precarcinogen PhIP. Expression of UGT1A7*2 demonstrated substantially reduced overall UGT activity with preservation of carcinogen metabolite glucuronidation (table 2). Preservation of this activity may explain the high incidence of N129K/R131K in the normal population represented in the UGT1A7*2/*1 (21%) and UGT1A7*2/*2 (16%) alleles. The lowest glucuronidation activity was found with the UGT1A7*3 allele, which confirms previous data.15 In an earlier study, UGT1A7 activities were analysed using stably transfected HEK cell clones in addition to a higher concentration of UDP-glucuronic acid in the UGT enzymatic assays. In our assay, UGT1A7*3 was characterised by undetectable UGT activity with the substrates shown in table 2, which was confirmed by several individual transfection experiments. Although Guillemet et al showed some remaining UGT activity of UGT1A7*3 in their stably expressing clones, both studies arrived at the conclusion that UGT1A7*3 represented the allele with the least benzo(a)pyrene metabolite glucuronidation activity. The catalytic analysis supports the finding that the UGT1A7*3 allele is significantly associated with the cancer group, identifying it as the main risk allele of CRC.

The magnitude of the altered catalytic activities encoded by the polymorphic alleles is an unexpected finding based on structural and biological considerations. The UGT1A7*3 allele has three amino acid changes, all of which were conserved with either UGT1A8 or UGT1A9 (fig 2). The high degree of homology between UGT1A7, UGT1A8, UGT1A9, and UGT1A10 has led to the assumption of great similarity of substrate specificity, as evidenced by glucuronidation of many phenolic compounds.16 However, examined in the absence of homology to other UGTs, these changes could be perceived to

<table>
<thead>
<tr>
<th>Substrate</th>
<th>UGT1A7*1 wild-type</th>
<th>UGT1A7*2 W208RNI129K/R131K</th>
<th>UGT1A7*3 W208RNI129K/R131K/W208R</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-Nitrophenol</td>
<td>1773 (615)</td>
<td>32 (23)</td>
<td>13 (2)</td>
</tr>
<tr>
<td>1-Naphthol</td>
<td>592 (100)</td>
<td>36 (16)</td>
<td>nd</td>
</tr>
<tr>
<td>4-Methylumbelliferone</td>
<td>12110 (361)</td>
<td>191 (136)</td>
<td>13 (2)</td>
</tr>
<tr>
<td>4-tert-Butylphenol</td>
<td>121 (2)</td>
<td>nd</td>
<td>12 (0.2)</td>
</tr>
<tr>
<td>7-Hydroxybenzo(a)pyrene</td>
<td>1263 (20)</td>
<td>51 (10)</td>
<td>14 (0.5)</td>
</tr>
<tr>
<td>8-Hydroxybenzo(a)pyrene</td>
<td>98 (8)</td>
<td>nd</td>
<td>12 (1)</td>
</tr>
<tr>
<td>7-8-Hydroxybenzo(a)pyrene</td>
<td>79 (7)</td>
<td>nd</td>
<td>15 (1)</td>
</tr>
<tr>
<td>9-Hydroxybenzo(a)pyrene</td>
<td>198 (15)</td>
<td>nd</td>
<td>16 (3)</td>
</tr>
<tr>
<td>PhIP</td>
<td>48 (4)</td>
<td>nd</td>
<td>17 (5)</td>
</tr>
</tbody>
</table>

Mean catalytic activities of the missense mutations identified in exon 1 of UGT1A7. The wildtype UGT1A7*1 exhibited high activities with phenolic compounds as well as with benzo(a)pyrene metabolites, as previously characterised.1 The analysis demonstrates reduced glucuronidation activities of the polymorphic UGT1A7*4 proteins. The major risk allele identified in the patient analysis, UGT1A7*3, exhibited the lowest carcinogen detoxification activity. PhIP, amino-1-methyl-6-phenylimidazo-(4,5-b) pyridine (PhIP), nd, not detected. Values are mean (SD).

Figure 4  Graphic representation of the association of polymorphic UGT1A7 alleles with sporadic colorectal cancer. A highly significant association was apparent for the wild-type alleles in normal control subjects without tumour and for the UGT1A7*3 allele with sporadic colorectal cancer. All numbers are in per cent (compare with table 1). All controls and colorectal cancer patients were of Northern German Caucasian descent. Statistical analysis (two tailed Fisher’s exact test): *p<0.05, ***p<0.001.
impact on function as the N129K and W208R differences represent non-conservative substitutions.

The majority of CRC patients with the UGT1A7*3 (129K/131K/208R) genotype were heterozygous (table 1). Similar findings have been reported for the mismatch repair genes in familial CRC. In the UGT1A genes, the presence of heterozygous mutant alleles with a reduced activity towards carcinogens can be influenced by additional occurrence of polymorphisms in exons 2–5 which are common to all UGT1A gene products. This combination would introduce an added risk factor capable of modifying the catalytic activity of all UGT1A proteins and would exert an increased influence on the already altered activity of polymorphic UGT1A7 alleles described in this study. In view of the previous identification of 20 individual polymorphisms located within the common UGT1A exon 2–5 sequences (reviewed by Tukey and Strassburg), additional combinations with the UGT1A7 polymorphisms described here are likely.

Our findings implicate the combination of genetic predisposition and environmental factors via the cellular detoxifying enzyme UGT1A7 in human CRC. The UGT1A7*3 allele exhibited a highly significant association with CRC. It was present in only 27% of the normal population studied (allelic frequency 0.17) but a tumour free state at the time of blood sampling does not preclude the development of CRC in normal controls at a later time. This suggests that screening for the presence of UGT1A7*3 would have a negative predictive value of 73%. Screening for 129K/131K/208R of the human UGT1A7 gene in selected patients may represent an attractive diagnostic tool to identify interindividual CRC risk profiles. Based on these findings, sporadic CRC may have a higher degree of individual genetic predisposition than previously thought. As CRC is a potentially curable disease when diagnosed at an early stage, the clinical implementation of our findings has the potential to improve the primary prevention of CRC in risk groups and to affect the decision process for endoscopic evaluation. In addition, UGT1A7 may serve as an attractive candidate gene for gene therapeutic strategies.

ACKNOWLEDGEMENTS

This work was supported by grants from the German Cancer Fund (Deutsche Krebshilfe) No 10-1668-St I and Deutsche Forschungsgemeinschaft (DFG) 493/3-3 (to CPS), and the United States Public Health Service Grant CA79834 (RHT). CPS is a recipient of a Heisenberg award of the Deutsche Forschungsgemeinschaft. The assistance of Dr S Kubicka, Department of Gastroenterology and Hepatology, Hannover Medical Center, as well as Drs Lahner and Guderlet, Central Hospital St Jürgenstr, Bremen, in blood sample procurement and the excellent technical assistance of Ayse Barut are gratefully acknowledged.

References